Associate Professor Sylvia Gustin

What is the analgesic effect of EEG neurofeedback for people with chronic pain? A systematic review

Researchers: A/Prof Sylvia Gustin, Dr Negin Hesam-Shariati, Dr Wei-Ju Chang, A/Prof James McAuley, Dr Andrew Booth, A/Prof Toby Newton-John, Prof Chin-Teng Lin, A/Prof Zina Trost

Chronic pain is a global health problem, affecting around one in five individuals in the general population. The understanding of the key role of functional brain alterations in the generation of chronic pain has led researchers to focus on pain treatments that target brain activity. Electroencephalographic (EEG) neurofeedback attempts to modulate the power of maladaptive EEG frequency powers to decrease chronic pain. Although several studies provide promising evidence, the effect of EEG neurofeedback on chronic pain is uncertain. This systematic review aims to synthesise the evidence from randomised controlled trials (RCTs) to evaluate the analgesic effect of EEG neurofeedback.

The search strategy will be performed on five electronic databases (Cochrane Central, MEDLINE, Embase, PsycInfo, and CINAHL) for published studies and on clinical trial registries for completed unpublished studies. We will include studies that used EEG neurofeedback as an intervention for people with chronic pain. Risk of bias tools will be used to assess methodological quality of the included studies. RCTs will be included if they have compared EEG neurofeedback with any other intervention or placebo control. The data from RCTs will be aggregated to perform a meta-analysis for quantitative synthesis. In addition, non-randomised studies will be included for a narrative synthesis. The data from non-randomised studies will be extracted and summarised in a descriptive table. The primary outcome measure is pain intensity assessed by self-report scales. Secondary outcome measures include depressive symptoms, anxiety symptoms, and sleep quality measured by self-reported questionnaires. Further, we will investigate the non-randomised studies for additional outcomes addressing safety, feasibility, and resting-state EEG analysis.

The RESTORE Trial: Immersive Virtual Reality Treatment for Restoring Touch Perception in People with

Chief Investigators: Associate Professor Sylvia Gustin, Prof James Middleton, A/Prof Zina Trost, Prof Ashley Craig, Prof Jim Elliott, Dr Negin Hesam-Shariati, Corey Shum and James Stanley

While recognition of surviving pathways in complete injuries has tremendous implications for SCI rehabilitation, currently no effective treatments exist to promote or restore touch perception among those with discomplete SCI. The proposed study will address this need by developing and testing a novel intervention that can provide touch restoration via the primary source of sensory perception: the brain.Complete spinal cord injury (SCI) is associated with a complete loss of function such as mobility or sensation. In a recent discovery we revealed that 50% of people with complete SCI still have surviving somatosensory nerve fibres at the level of the spine. For those with complete SCI this is hopeful news as it means — contrary to previous belief that communication to the brain had been severed by injury — that the brain is still receiving messages. This new SCI type is labelled “discomplete SCI” — a SCI person who cannot feel touch, but touch information is still forwarded from the foot to the brain.

The project will use virtual reality (VR) in a way it has never been used before. We will develop the first immersive VR interface that simultaneously enhances surviving spinal somatosensory nerve fibres and touch signals in the brain in an effort to restore touch perception in people with discomplete SCI. In other words, immersive VR is being used to re-train the brain to identify the distorted signals from toe to head as sensation (touch). For example, participants will receive touch simulation in the real world (e.g., their toe) while at the same time receiving corresponding multisensory touch stimuli in the virtual world (e.g., experiencing walking up to kick a ball).

This project is the first effort worldwide to restore touch sensation in 50% of individuals with complete injuries. The outcomes to be achieved from the current study will represent a cultural and scientific paradigmatic shift in terms of what can be expected from life with a spinal cord injury. In addition, the project allows potential identification of brain mechanisms that may ultimately represent direct targets for acute discomplete SCI rehabilitation, including efforts to preserve rather than restore touch perception following SCI.

RESTORE consolidates the expertise of scientists, clinicians, VR developers and stakeholders from NeuRA and UNSW School of Psychology (A/Prof Sylvia Gustin, Dr Negin Hesam-Shariati), John Walsh Centre for Rehabilitation Research, Kolling Institute and University of Sydney (Prof James Middleton, Prof Ashley Craig and Prof Jim Elliott), Virginia Commonwealth University (A/Prof Zina Trost), Immersive Experience Laboratories LLC (Director Corey Shum) and James Stanley.

If you are interested in being contacted about the RESTORE trial, please email A/Prof Sylvia Gustin (s.gustin@unsw.edu.au) and include your name, phone number, address, type of SCI (e.g., complete or incomplete), level of injury (e.g., T12) and duration of SCI (e.g., 5 years).

Medicines for Back Pain

The No Worries Trial

Researchers: Associate Professor Sylvia Gustin, Nell-Norman-Nott, Dr Negin Hesam- Shariati, Dr. Chelsey Wilks (University of Washington).

Emerging evidence has shown that negative emotional states play a key role in the development and maintenance of chronic pain. The No Worries Trial will evaluate the effectiveness of a four-week internet-delivered Dialectical Behaviour Therapy (DBT) skills training to help chronic pain sufferers cope with painful, fearful, worrisome, anxious, and negative thoughts and emotions. Moreover, by having the DBT skills training online it is more accessible to those in remote communities, to those with restricted mobility, and more broadly it adds to the knowledge of internet-delivered therapies at a time when online is increasingly necessary to deliver treatment due to COVID-19.

MEMOIR – a clinical trial for Complex Regional Pain Syndrome

Complex Regional Pain Syndrome (CRPS) is a disabling pain disorder, affecting approximately 5,000 people in Australia annually. It is characterised by severe burning, stinging and stabbing pain. People with CRPS are unable to use their painful limb and their ability to work or participate in normal social activities is severely restricted. Currently, there are no effective treatments for CRPS.

The MEMOIR Trial is a Commonwealth Government-funded, randomised controlled trial testing two novel treatments for CRPS. MEMOIR will test whether a drug, memantine, and a rehabilitation program, Graded Motor Imagery (GMI), produce greater improvements in pain intensity and function than placebo and standard care for CRPS.

The MEMOIR trial will be delivered remotely, via Telehealth, allowing Australia-wide recruitment of participants. Recruitment for MEMOIR will begin in early 2021. If you are interested in being contacted once recruitment has begun, please enter your details below.

MEMOIR Investigators

MEMOIR consolidates the expertise of scientists and clinicians:

• A/Prof James McAuley, School of Medical Sciences & NeuRA, University of New South Wales
• A/Prof Sylvia Gustin, School of Psychology & NeuRA, University of New South Wales
• Prof Andrew McLachlan, Dean of Pharmacy, University of Sydney
• Prof Lorimer Moseley, University of South Australia
• Prof Benedict Wand, School of Physiotherapy, University of Notre Dame Australia
• Dr Neil O’Connell, Brunel University London
• Dr Hopin Lee, University of Oxford
• Prof Eric Visser, School of Medicine, University of Notre Dame Australia
• Prof Sallie Lamb, University of Exeter
• Mr Michael Ferraro, NeuRA, University of New South Wales

 

Spinal Cord Injury Breakthrough

Associate Professor Sylvia Gustin, Associate Professor Paul Wrigley and Professor Philip Siddall.

Researchers from NeuRA, the University of New South Wales
the University of Sydney,
and HammondCare have found surviving sensory spinal nerve connections in 50 per cent of people living with complete thoracic spinal cord injuries.

The study, which is part of
a decade-long collaboration between the researchers, used cutting-edge functional MRI (fMRI) technology to record neural response to touch. It was  Dr Sylvia Gustin who analysed the fMRI images to identify the moment the patient’s brain registered the touch.

“Seeing the brain light up to touch shows that despite the complete injury to the thoracic spine, somatosensory pathways have been preserved,” explains Dr Gustin.

“It’s fascinating that although the patients did not ‘feel’ the big toe stimulation in the experiment, we were able to detect a significant signal in response to the touch in the brain’s primary and secondary somatosensory cortices, the thalamus, and the cerebellum.”

For those living with a complete spinal cord injury this means, despite previously believing
the communication to the brain had been severed in the injury, messages are still being received. Dr Gustin describes this new category of spinal cord injury as ‘discomplete’

“The current classification system is flawed. It only contains two types of spinal cord injury – complete and incomplete,” says Dr Gustin.

“It is important we acknowledge there is a third category – the ‘discomplete’ injury, only then we can provide better treatment regimens for the many sufferers of a complete spinal cord injury.”

For those newly classified as ‘discomplete’, this discovery opens up new opportunities to identify those people living with a spinal cord injury that are more likely to benefit from treatments aimed at improving sensation and movement. Because of this study, research participant, James Stanley, now knows he belongs to a new category.

“It is exciting to know that there
is a connection there, that my toe is trying to say hello to my brain,” says James.

“If medical professionals can work to identify people like me with a ‘discomplete’ injury earlier, perhaps they can find new treatments and rehabilitation techniques.

“The thought that one day I might be able to feel the sand between my toes again, or the waves wash over my feet gives me hope. It’s something Dr Gustin’s discovery has made possible.”

 

The Avatar Project – Virtual Reality Intervention

The STOPain Study: Using brain-computer-interface intervention for people with neuropathic pain

Chronic pain is a significant problem worldwide affecting nearly 8 million Australians. Unfortunately, despite the availability of analgesics and other pain therapies, no treatment has been found that benefits the majority of individuals, and most of the available treatments have significant side effects or risks for serious adverse events, e.g. kidney failure.

Unravelling the link between chronic pain and mental health disorders

Chronic pain is a significant problem worldwide that results in enormous suffering and costs to affected individuals, their loved ones, and society. The experience of chronic pain is so much more than a sensation. Chronic pain impacts our emotions, cognition and social life.

A Multi-Site Randomized Clinical Trial to Examine the Efficacy and Mechanisms of Immersive Virtual W

Chronic neuropathic pain (NP) can be a debilitating secondary condition for persons with spinal cord injury (SCI) and effective pharmacological and non-pharmacological treatments remain elusive. This project brings together international experts in basic science and clinical approaches to SCI NP for a rigorous multisite randomized clinical trial to examine the efficacy and mechanisms of an advanced interactive virtual reality (VR) walking intervention (VRWalk).

RESOLVE Trial for Chronic Low Back Pain

For people with long term back pain that is not getting better. We are testing two pain treatment programs that target the brain, for people with chronic low back pain.

Patient Education to PREVENT Chronic Low Back Pain

For people with a new low back pain episode. We are testing early intervention to reduce the risk of developing chronic low back pain.

SLEEPain

For people with back pain who are having trouble with their sleep. We are testing whether a simple sleep tablet will help people reduce their pain and sleep better.